Objective

To validate the Italian version of the Myasthenia Gravis Impairment Index (MGII).

Introduction

MGII is a recent promising measure developed for MG patient evaluation. It includes a clinical severity evaluation and a patient-reported questionnaire. It has been developed in English and has demonstrated feasibility, reliability, and construct validity. Recently, its Dutch translation has been validated.

Methods

MGII was translated to Italian with a multi-step forward process. We assessed correlations with the following scores: Istituto Nazionale Carlo Besta score for Myasthenia Gravis (INCB-MG), the MG Activities of Daily Living (MG-ADL), the Myasthenia Gravis Composite (MGC), the Quality of Life 15 for Myasthenia Gravis (QOL15-MG), and the Myasthenia Gravis Disability (MGDIS). We also assessed differences in MGII scores by disease severity with the ANOVA Kruskal–Wallis test.

Results

One hundred forty-one patients were enrolled. The mean MGII total score was 13.3 ± 11.9 (range 0–49), with a mean ocular subscore of 3.7 ± 4.7 and a mean MGII generalized subscore of 9.6 ± 9.0. As expected, the MGII had a good correlation with the other severity scores. The MGII had a lower floor effect (3.5%) than the other measures. Twenty-five patients were assessed in follow-up; as expected, the MGII change scores had moderate correlations with change in other MG severity measures and lower correlations with quality of life measures.

Conclusions

The MGII score was cross-culturally validated in an Italian cohort of MG patients. We confirmed its lower floor effect and the correlations with other MG measures including INCB-MG that was not evaluated in previous studies.

中文翻译：

---

意大利版重症肌无力损伤指数 (MGII) 的验证

客观的

验证意大利版重症肌无力损伤指数 (MGII)。

介绍

MGII 是最近为 MG 患者评估开发的有希望的测量方法。它包括临床严重程度评估和患者报告的问卷。它是用英语开发的，并且已经证明了可行性、可靠性和结构效度。最近，它的荷兰语翻译得到了验证。

方法

MGII 通过多步推进过程被翻译成意大利语。我们评估了以下分数的相关性：重症肌无力 (INCB-MG)、MG 日常生活活动 (MG-ADL)、重症肌无力综合 (MGC)、重症肌无力生活质量 15 (QOL15-MG) 和重症肌无力残疾 (MGDIS)。我们还使用 ANOVA Kruskal-Wallis 检验评估了疾病严重程度的 MGII 评分差异。

结果

141 名患者入组。平均 MGII 总分为 13.3 ± 11.9（范围 0-49），平均眼部评分为 3.7 ± 4.7，平均 MGII 广义评分为 9.6 ± 9.0。正如预期的那样，MGII 与其他严重程度评分具有良好的相关性。MGII 的地板效应 (3.5%) 低于其他措施。对 25 名患者进行了随访评估；正如预期的那样，MGII 变化评分与其他 MG 严重程度测量的变化具有中度相关性，而与生活质量测量的相关性较低。

结论

MGII 评分在意大利 MG 患者队列中进行了跨文化验证。我们证实了它的下限效应以及与其他 MG 措施的相关性，包括以前研究中未评估的 INCB-MG。